BIONET Therapeutics Corp. (TPEX:7808)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
49.80
-0.50 (-0.99%)
At close: Feb 26, 2026
-13.99%
Market Cap 3.49B
Revenue (ttm) 105.67M
Net Income (ttm) -100.46M
Shares Out 70.00M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 156,115
Average Volume 48,468
Open 51.20
Previous Close 50.30
Day's Range 49.00 - 51.20
52-Week Range 37.70 - 66.30
Beta n/a
RSI 29.49
Earnings Date Mar 20, 2026

About BIONET Therapeutics

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney disease, acute wound healing, chronic wound healing of diabetic ulcers, and osteoarthritis. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2022
Employees 73
Stock Exchange Taipei Exchange
Ticker Symbol 7808
Full Company Profile

Financial Performance

In 2024, BIONET Therapeutics's revenue was 81.32 million, an increase of 1414.60% compared to the previous year's 5.37 million. Losses were -86.26 million, 131.0% more than in 2023.

Financial Statements

News

There is no news available yet.